Aurobindo Pharma has announced robust financial results for the quarter and year ended March 31, 2026, showcasing significant growth in both revenue and profit. The company reported a consolidated annual revenue of ₹3,36,530.8 million and an annual profit after tax of ₹35,029.7 million. Alongside these financial achievements, the company confirmed strategic board decisions regarding internal restructuring, the appointment of new secretarial auditors, and its ongoing global expansion efforts.
Annual Financial Performance Highlights
For the financial year ended March 31, 2026, Aurobindo Pharma achieved a strong consolidated financial performance. The company’s consolidated revenue from operations climbed to ₹3,36,530.8 million, compared to ₹3,17,237.3 million in the previous year. The consolidated profit after tax for the year stood at ₹35,029.7 million, reflecting sustained operational efficiency despite market challenges.
On a quarterly basis for Q4 (Jan-Mar 2026), the company recorded consolidated revenue of ₹88,533.4 million, with a profit after tax of ₹9,208.4 million, marking a positive conclusion to the fiscal year.
Strategic Acquisitions and Corporate Developments
Aurobindo Pharma continues to expand its global footprint and domestic presence. Throughout the fiscal year, the company incorporated several new subsidiaries across various global markets, including Netherlands, Malaysia, Chile, and the Philippines. Additionally, the company is moving forward with the acquisition of Lannett Company LLC in the US, pending regulatory approvals.
Domestically, the company has taken proactive steps in internal restructuring. This includes the transfer of its domestic branded generic pharmaceutical formulations business to its wholly owned subsidiary, Auropharm Limited, effective April 1, 2026. Furthermore, the company successfully completed a ₹8,000 million share buyback program, paying eligible shareholders on May 7, 2026.
Governance and Administrative Updates
The company announced changes in its administrative and audit teams. Following the resignation of M/s. MRR & Associates due to health reasons, M/s. RPR & Associates has been appointed as the new Secretarial Auditor for a five-year term starting from the 2026-27 fiscal year. Additionally, M/s. Ernst & Young LLP has been re-appointed as the company’s internal auditor for the period ending May 2027.
Source: BSE
